The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer

By afschroeder • March 24, 2026

Cecchini M, Han SW, Lee S, Lee KW, Kopetz S, Mizrahi J, Hong YS, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao T, Khemka V, Wainberg ZA. The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer. Clin Cancer Res. 2026 Mar 23. doi: 10.1158/1078-0432.CCR-25-3727. Epub ahead of print. PMID: 41870279.

Tags: Hematology/Oncology, Publications

Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis

Ravani LV, Bagheri Z, Kalinsky K, Burstein HJ, Bardia A, Mouabbi JA, O'Regan R, Wander SA. Progression-Free Survival in Metastatic Breast Cancer by Local Investigators[...]

Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate

Schoen MW, Li J, Zeng S, Desai H, Hausler R, Haroldsen CL, Owens L, Valle LF, Etzoni RB, Rebbeck TR, Rose BS, Kelley MJ, Montgomery[...]

Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis

Tai D, Kim KI, Shah P, Park D, Kim L, Li J, Jung C, Guzman S, Brar G, Wu S, Castillo D. Impact of metastatic[...]